We are live on ! Find out more
KIN

Kindred Biosciences
KIN

Delisted

KIN was delisted on the 27th of August, 2021.

71 hedge funds and large institutions have $241M invested in Kindred Biosciences in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.77% less ownership

Funds ownership: 66.67% → 64.91% (-1.8%)

12% less funds holding

Funds holding: 81 → 71 (-10)

30% less capital inflows, than outflows

Capital inflows: $14.5M | Capital outflows: $20.8M

32% less call options, than puts

Call options by funds: $89K | Put options by funds: $130K

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

Holders
71
Holders Change
-10
Holders Change %
-12.35%
% of All Funds
1.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
27
Reduced
22
Closed
19
Calls
$89​K
Puts
$130​K
Net Calls
-⁠$41​K
Net Calls Change
-⁠$138​K

KIN Hedge Fund Activity: Q4 2018 in Review

71 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences (KIN) for Q4 2018, worth a combined $241M — down 23% from $314M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KIN and 9 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 27 added.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $2.14M. The largest seller was Morgan Stanley, cutting an estimated $4.35M.

  • 71 institutional investors held Kindred Biosciences (KIN) as of Q4 2018, down from 81 in Q3 2018.
  • Funds reported $241M of Kindred Biosciences stock for Q4 2018, down 23% quarter-over-quarter.
  • 9 funds opened new Kindred Biosciences positions in Q4 2018 and 19 closed out, a net change of -10 holders.
  • The largest Kindred Biosciences buyer in Q4 2018 was Assenagon Asset Management, an estimated $2.14M added.
  • The largest Kindred Biosciences seller in Q4 2018 was Morgan Stanley, an estimated $4.35M sold.

Based on aggregated 13F filings for Q4 2018.